Terminated PHASE4 INTERVENTIONAL 3-arm NCT00206375

Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism

Concomitant Use of Growth Hormone and GnRH Agonist in Adolescent Patients With Acquired Hypothyroidism

Sponsor: Baylor College of Medicine

Interventions Growth hormone Growth hormone treatment and puberty

Updated 6 times since 2017 Last updated: Oct 26, 2020 Started: May 31, 2003 Primary completion: Sep 30, 2011 Completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Baylor College of Medicine

See all terminations from Baylor College of Medicine

Other Hypothyroidism trials with similar outcome

Browse all Hypothyroidism trials

Listed as NCT00206375, this PHASE4 trial focuses on Hypothyroidism and remains terminated or withdrawn. Sponsored by Baylor College of Medicine, it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE4

Status: Completed → Terminated
Jun 2018 — Nov 2020 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baylor College of Medicine
Eli Lilly and Company
TAP Pharmaceutical Products Inc.

Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States